Skip to main content
Stock Expert AI
Earnings Watch INTERMEDIATE ✨ AI Enhanced

Moderna (MRNA) Posts Q3 2026 Profit as Revenue Tops Estimates

9 min read Data as of 4 sources
MRNA$254.19+5.27%Today, Nov 20, 2026: 31/100

AI-generated editorial content. For informational purposes only. Not financial advice.

Moderna — Journal cover

Stock Expert AI data cover: figures from Financial Modeling Prep. Photo credit and licence on the image

Moderna (MRNA) reported diluted earnings of $0.38 per share for the third quarter ended Sept. 30, 2026, against an analyst estimate of a loss of $1.1 per share, on revenue of $1.31B versus an estimate of $890.3M. A year earlier, in the third quarter ended Sept. 30, 2025, it lost $0.51 per share on revenue of $1.02B. The profit is real, but the quarter's cash flow was negative, and that tension is the story. Figures are current as of Nov. 6, 2026.

Key facts

  • Nov. 6, 2026 (Q3 FY2026, ended Sept. 30, 2026): diluted EPS was $0.38 versus an estimate of a loss of $1.1 per share, a difference of +$1.48.
  • Revenue: $1.31B versus an estimate of $890.3M (+$422.7M). It was up 29.2% from $1.02B in the year-ago quarter.
  • Net income: $162.0M, versus a loss of $200.0M in Q3 FY2025.
  • Stock: $254.19 on the latest quote as of Nov. 6, 2026, up 5.27% on the day. The 52-week range is $22.28 to $267.5.
  • Guidance: management raised its full-year 2026 revenue growth outlook to 15% to 25%, according to the earnings call.
MetricQ3 FY2026Year-ago or estimate
Diluted EPS$0.38Estimate: loss of $1.1; year-ago: loss of $0.51
Revenue$1.31BEstimate: $890.3M; year-ago: $1.02B
Operating income$130.0MYear-ago: loss of $260.0M
Net income$162.0MYear-ago: loss of $200.0M

What happened

Moderna swung from a loss to a profit in a single quarter. Operating income, which is profit from the core business before interest and taxes, was $130.0M, compared with a loss of $260.0M a year earlier. Net income was $162.0M, against a loss of $200.0M in the third quarter of 2025. CFO James Mock described that as an improvement of $362 million compared with last year.

By region, the United States brought in $771.0M of revenue, Europe $314.0M and the rest of the world $188.0M.

Management gave several reasons. On the call, the company said US demand and execution improved, with stronger uptake of its newer COVID vaccine, MNEXSPIKE, and vaccination rates described as relatively stable year over year. It also credited international partnerships in the UK, Canada and Australia. It said shipment timing between the third and fourth quarters made Q3 revenue stronger than expected, which means some sales may have been pulled forward.

Costs also fell. Management said research spending dropped as infectious disease studies wound down and efficiency gains took hold. It lowered its full-year research and development outlook and its capital spending outlook.

CEO Stéphane Bancel summed up the quarter this way: "Strong sales growth, profitability, approval and quick launch of flu in the U.S., intismiran positive Phase 3, and the convert that financing." The call transcript is automated and may contain errors.

On flu, CFO James Mock said in the Q&A that it is "relatively immaterial right now, for us. In 2026..." and that the company expects it to grow next year.

A five-quarter view

The quarter looks more dramatic against recent history. Revenue in the quarters ended Sept. 30, 2025, Dec. 31, 2025, March 31, 2026 and June 30, 2026 was $1.02B, $678.0M, $389.0M and $145.0M. It then jumped to $1.31B. Management pointed to an ongoing vaccination season and to shipment timing between the third and fourth quarters as factors behind the third-quarter strength.

Operating margin, the share of revenue left as operating profit, moved from -25.6% to -126.4%, then -356.8%, then -562.1%, before reaching 9.9% in the latest quarter. Gross margin was 75.8% in Q3 FY2026, up from 35.9% in the prior quarter. A margin this high on one quarter does not tell us what a full year looks like.

Why it matters for investors

Cash flow tells a different story than earnings. In Q3 FY2026, operating cash flow was a loss of $1.56B and free cash flow (cash left after capital spending) was a loss of $1.61B. The prior two quarters also had negative free cash flow, at a loss of $563.0M in Q2 and $692.0M in Q1. The CFO said cash and investments rose in the quarter, helped by $2.6 billion of net convertible note proceeds, partly offset by a $950 million payment on a previously announced litigation settlement and the seasonal impact on working capital. Separately, Reuters reported on Nov. 6 that Moderna and GSK settled a patent dispute; the evidence we reviewed does not tie that deal to the Q3 payment. For the full year, the CFO said the cost of sales framework of $1.7 billion includes $900 million of expense related to the previously announced litigation settlement charge. Q3 cost of sales itself was $318 million.

The balance sheet is stable for now. As of Sept. 30, 2026, FMP shows Moderna held $5.17B in cash and short-term investments against $4.18B in total debt, for net debt of $2.98B. Shareholders' equity was $6.84B. The CFO, by contrast, said cash and investments were $8 billion at quarter-end. The gap likely reflects longer-term investments that FMP's cash line does not include, though we could not confirm that. It matters because the CFO's year-end guidance of $8.1 billion to $8.3 billion is measured against his $8 billion figure, not FMP's. Management said it raised money through a convertible note, which is debt that can later turn into shares. Its Altman Z-score, a bankruptcy-risk gauge where higher is safer, is 9.73. Its Piotroski score, a 0-to-9 measure of financial health, is only 3.

Valuation is demanding on trailing numbers. Over the trailing 12 months, Moderna's price-to-sales ratio is 40.19 and its net margin is -110.5%. Its P/E is -35.95, which is negative because of the losses. Peers vary widely:

CompanyMarket capP/ENet margin
Moderna (MRNA)$101.48B-35.95-110.5%
BioNTech (BNTX)$21.70B-13.29-61.5%
GSK (GSK)$101.80B17.5013.0%
Arcturus (ARCT)$294.2M-3.34-312.9%
Inovio (INO)$83.9M-1.040.0%

GSK has a similar market cap but is profitable and trades at a positive P/E. BioNTech, a closer vaccine peer, is also loss-making.

Analysts are well below the share price. Among 29 analyst ratings, 7 are buy, 16 hold and 6 sell, for a consensus of Hold. The average price target is $132.70, with a range of $25.00 to $245.00. The latest quote of $254.19 is above the highest target. On Oct. 27, 2026, William Blair downgraded the stock from Outperform to Market Perform. FMP's discounted cash flow model value is -$1.59 per share, which reflects how far current cash flows are from supporting the price. In the last 90 days, the filings we reviewed show 0 open-market insider purchases and 7 sales.

Our MoonshotScore is Weak. Stock Expert AI's MoonshotScore V2 for Moderna is 31.1, rated Weak. Among the sector-relative pillars, momentum is 100, the strongest possible, while safety is 47, valuation 42, growth 23 and quality 19. In plain terms, the share price has run hard, but growth and business quality still rank low against the sector.

What could go wrong

  • Norovirus vaccine: management said the Phase 3 trial missed its interim early-success criteria, with health authority discussions pending.
  • COVID demand: vaccination was trending slightly behind last year through late October, though management said October momentum suggested flat year over year.
  • Regulatory timing: the US filing decision for its combination flu and COVID vaccine depends on further FDA discussion, and several approvals remain under review.
  • Early cancer data: on pancreatic cancer, management said it was probably too early to read the early efficacy signal.
  • Shipment timing: some Q3 strength may have come from shipments that would otherwise have landed in Q4.

What to watch next

  • Next earnings: the next report is expected on Feb. 12, 2027, and should cover the fourth quarter of fiscal 2026, ended Dec. 31, 2026. FMP's estimate for it is a loss of about $1.73 per share on revenue of $675.4M. For later quarters, analysts' estimate for the period ending March 30, 2027, is revenue of $264.3M and a loss of $1.72 per share, and for the period ending June 30, 2027, revenue of $120.4M and a loss of $1.92 per share. Management gave no quarterly guidance.
  • Cancer program: the intismiran melanoma trial showed a 42% reduction in the risk of recurrence or death, according to the CEO, and the company targets a filing in 2026. A kidney cancer interim readout is event-driven and could come at the end of 2026 or in early 2027.
  • Cash burn: whether free cash flow turns positive in the fourth quarter. Q4 FY2025 free cash flow was positive $912.0M, which is why the quarter's cash is worth watching.
  • Cost control: management said it lowered full-year research and cash cost expectations, so watch whether that holds.

Frequently asked questions

Q: Did Moderna beat earnings estimates in the third quarter of 2026?

Yes. For the quarter ended Sept. 30, 2026, Moderna reported diluted EPS of $0.38 against an analyst estimate of a loss of $1.1 per share. Revenue was $1.31B versus an estimate of $890.3M. Year-ago EPS was a loss of $0.51.

Q: Is Moderna profitable now?

Only for the latest quarter. Moderna earned net income of $162.0M in the quarter ended Sept. 30, 2026. Over the trailing 12 months its net margin is still -110.5%, and free cash flow in the quarter was a loss of $1.61B. One strong quarter does not make a full year profitable.

Q: What do analysts think of Moderna stock after earnings?

The consensus rating is Hold, with 7 buy, 16 hold and 6 sell ratings among 29 analysts. The average price target is $132.70 and the range runs from $25.00 to $245.00, while the latest quote as of Nov. 6, 2026 was $254.19. This is not a recommendation.

What our data could not verify

We could not confirm how much of the quarter's revenue was pulled forward from the fourth quarter, nor the exact split of one-time items in cash flow. The call transcript is automated and may contain errors. Segment figures from the data provider were unclear on period, so we did not use them. Older insider filings may be missing.

Sources: Stock Expert AI data (MoonshotScore); FMP financial data and analyst consensus as of Nov. 6, 2026; Moderna's Q3 2026 earnings call; third-party reports from Reuters and Zacks for context only.

This is educational content, not investment advice. Past performance does not guarantee future results.

What to watch next

  1. Next earnings: the next report is expected on Feb. 12, 2027, and should cover the fourth quarter of fiscal 2026, ended Dec. 31, 2026. FMP's estimate for it is a loss of about $1.73 per share on revenue of $675.4M. For later quarters, analysts' estimate for the period ending March 30, 2027, is revenue of $264.3M and a loss of $1.72 per share, and for the period ending June 30, 2027, revenue of $120.4M and a loss of $1.92 per share. Management gave no quarterly guidance.

MRNA on Stock Expert AI

MoonshotScore 31/100 Nov 20, 2026

A 0-100 score built from five sections.

  • Quality20
  • Safety24
  • Valuation41
  • Growth41
  • Momentum99
🎯

MoonshotScore AI Ratings

Each stock is scored 0-100 on five pillars: Business Quality, Financial Safety, Valuation, Growth Durability and Momentum. A story quotes the score of the day it was written.

MRNA Today, Nov 20, 2026: 31/100

Related Tickers

earningsbiotechnology

Sources

Related Sectors & Industries

Related 2026 Trends

Next story

AI Signals CoreWeave (CRWV) reports Nov. 10 with growth strong and debt heavy 9 min readCRWV
👁 Editorial Transparency
🧠Content generated by AI editorial engine
👤Stock Expert AI Research is an AI editorial voice of Stock Expert AI
✅Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article.
🛡Financial Modeling Prep (FMP)
🕑Last updated:

Get the week's earnings in one Thursday email

The S&P 500 companies on that week's earnings calendar, each with its current MoonshotScore, plus the week's Journal research. Free, one email a week, with an unsubscribe link in every issue.

We send one confirmation email first and nothing else until you click its link (it works for 7 days). After that, the Weekly only. Your address is not sold or shared. Newsletter details · Free guide: How to read a MoonshotScore · Privacy Policy


Explore More Market Intelligence

Evidence & Sources

  • Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures.
  • MoonshotScore V2 rates eligible US-listed companies from 0 to 100 against their sector peers on five pillars: Business Quality (weight 26), Financial Safety (weight 20), Valuation (weight 18), Growth Durability (weight 16) and Momentum (weight 12). Weights are rescaled to 100 when all five pillars have data: 28.3%, 21.7%, 19.6%, 17.4% and 13.0% of the score. It reads no news-sentiment or analyst data, and it is not a probability of future returns.
  • Definitions follow standard investing terminology, with key terms explained inline in plain language where useful.
  • Each price is the last quote we recorded, shown with the trading session it belongs to. Pages are served from a cache, so the copy you are reading can lag that quote. Each quote is a provider snapshot, not an exchange feed.
  • This page is educational and does not constitute investment advice.
  • Numbers come from market data providers (FMP); AI writes the plain-English explanations around them, which should be verified with independent research.